tbuckley/cabot-search huggingface dataset:
Abstract B20: Single-cell profiling of EGFR-regulated protein changes involved in cell cycle, cell proliferation and apoptosis
Authors: Ilona Holcomb, Gajalakshmi Dakshinamoorthy, Benjamin Liu, Marc Unger, Ramesh Ramakrishnan, Haibiao Gong
Journal: Cancer Research (2016)

Abstract Single-cell molecular analysis has become increasingly important in biomedical research, especially in the field of cancer research, where cell heterogeneity is a characteristic feature. We developed a multiplexed single-cell protein detection assay for the C1™ system that can isolate and process 96 individual cells in parallel. The assay uses oligonucleotide-conjugated antibody binders and monitors the specific oligonucleotide levels instead of protein levels. The resulting DNA amplicon is detected by qPCR on the Biomark™ HD system. Data are analyzed using Singular™ Analysis Toolset. A total of 50 antibody binders were developed for this assay to target proteins related to apoptosis, cell cycle, cell proliferation, tumor suppressors, biomarkers, stem cells, growth factors and proteins associated with specific cancers, such as breast and prostate cancers. The assay can be performed in a 48-plex format which yields over 4,600 data points in two days. Assay sensitivity and specificity were assessed using recombinant proteins and various cell lysates. To demonstrate the usefulness of this assay, a panel of antibody binders was selected to profile the changes of proteins involved in cell cycle, cell proliferation and apoptosis in single cells. We treated cells that overexpress epidermal growth factor receptor (EGFR) with either the EGF ligand or the gefitinib receptor inhibitor and analyzed the changes in protein levels. Cells without EGFR expression were used as the control. EGFR is a member of ErbB family of Type I tyrosine kinases. EGFR overexpression and its mutations are involved in a variety of cancers. While much effort has been made to investigate the consequences of EGFR activation or inhibition, hardly any information is available regarding how EGFR regulation changes protein expression in single cells. Single-cell analysis—determining protein changes and analyzing the correlation between different proteins at the single-cell level—yields valuable information that is not achievable using bulk-cell analysis. Citation Format: Ilona Holcomb, Gajalakshmi Dakshinamoorthy, Benjamin Liu, Marc Unger, Ramesh Ramakrishnan, Haibiao Gong. Single-cell profiling of EGFR-regulated protein changes involved in cell cycle, cell proliferation and apoptosis. [abstract]. In: Proceedings of the Fourth AACR International Conference on Frontiers in Basic Cancer Research; 2015 Oct 23-26; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2016;76(3 Suppl):Abstract nr B20.
Postpsychotic state, convalescent environment, and therapeutic relationship in schizophrenic outcome
Authors: L Kayton, J Beck, S D Koh
Journal: American Journal of Psychiatry (1976)

The authors evaluated the following variables in the 2-3-year outcomes of 30 schizophrenic patients: the acute/chronic dichotomy, the presence of a postpsychotic regressive state, the quality of the convalescent environment, and the formation of a therapeutic relationship. They found that the presence of a postpsychotic regressive state was not associated with either good or poor short-term outcome; that the diagnosis of acute schizophrenia was almost invariably followed by good outcome, but a diagnosis of chronic schizophrenia had little predictive value; and that a favorable convalescent environment and the presence of a therapeutic relationship were signigicantly associated with good outcome.
Soundings: Doctors in poll position
Authors: Imre Loefler
Journal: BMJ (2005)

Doctors have the opportunity to turn the gears of medicalisation a notch further: the electorate ought to be medically certified before being allowed to vote.

There is a staggering number of voters with dementia. Their ranks are growing. It is estimated that by 2015 there will be 15 million people with dementia in the United States alone.

Not only are people with dementia incompetent to vote, but they are also easily manipulated. The exploitation of such people in the elections is a flagrant case of human rights abuse, not to speak of the corruption of the electoral process.

Doctors must step in. The medical profession already, usefully, contributes towards the decision as to who can go into space, fly an aeroplane, or drive a car, or who is fit to die in uniform, work in a mine, or do businesses in the tropics; it is only logical that doctors be asked to decide who can vote.

Fitness for flying planes or spacecraft, driving, military duty, working in a mine or for duty in the tropics is determined by well defined criteria such as eyesight, hearing, blood pressure, heart rate, pulmonary function. The task now is to define what the minimum criteria for voting competence are. This is clearly a matter for doctors.

Political interference with this important task is to be expected. All parties vie for the vote of people with dementia and will increasingly depend on it. Politicians therefore have an interest in ensuring that the minimum criteria are as basic as possible.

This the medical profession must not allow. Its contribution to the mental and corporeal sanity of the populace has always operated on a high moral platform—so it must remain when it comes to judging public sanity.

The test itself can easily be carried out in general practice, or alternatively by paramedics at the time of voter registration.

One question remains: for how long should the electoral licence be valid—two or four years? Most doctors are likely to think that two years is better; after all, it is well known that the mind can disintegrate fast. It would be reckless to allow people to remain on the licensed voters roll for four years. Society cannot do without consulting a competent authority for such a long period of time.
Human Breast Carcinoma Cell Levels of MDR-1 (P-Glycoprotein) Transcripts Correlate <i>In Vivo</i> Inversely and Reciprocally with Tumor Progesterone Receptor Content
Authors: B M Kacinski, L D Yee, D Carter, D Li, M T Kuo
Journal: Cancer Communications (1989)

Sixteen human breast carcinomas were subjected to molecular biological and biochemical analyses to determine tumor cell MDR-1 (P-glycoprotein) levels and progesterone receptor content. The results of these analyses disclosed a strong reciprocal and inverse correlation between levels of tumor cell-specific MDR-1 complementary hybrids and progesterone receptor content. These results suggest that the mechanisms which control expression of the P-glycoprotein gene and the progesterone receptor are interrelated and antagonistic, a result with obvious molecular biological, physiological, and clinical implications.
Azaguanine-Deaminase Activity of Several Lymphocytic Leukemias of Mice
Authors: Bernard Shacter, L. W. Law
Journal: JNCI Journal of the National Cancer Institute (1957)

Azaguanine-Deaminase Activity of Several Lymphocytic Leukemias of Mice Get access Bernard Shacter, Bernard Shacter National Cancer Institute,2Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar L. W. Law L. W. Law National Cancer Institute,2Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 18, Issue 1, January 1957, Pages 77–81, https://doi.org/10.1093/jnci/18.1.77 Published: 01 January 1957 Article history Received: 03 August 1956 Published: 01 January 1957
Is Rituximab Needed With High Dose Chemotherapy and Autologous Stem Cell Transplant When Patients With Non-Hodgkin’s Lymphoma Have Been Exposed To It?
Authors: Zartash Gul, Stephan Anderson, Stacey Slone, Saurabh Chhabra, Gregory Monohan, Dianna Howard, Amber Lawson, John Hayslip
Journal: Blood (2013)
Renal Lithiasis
Authors: Stephen M. Krane
Journal: New England Journal of Medicine (1962)

Uric Acid StonesUric acid stones are second in frequency to calcium stones. They are radiolucent and sometimes require intravenous or air pyelography for demonstration. The factors that predispose to the formation of this type of calculus are as follows: acid urine; high uric acid excretion; and dehydration. Henneman, Wallach and Dempsey12 and Atsmon et al.13 have emphasized the fact that the presence of a low urinary pH is the most important etiologic factor in the genesis of uric acid stones since the solubility of uric acid increases markedly with increasing pH above 6.5. Although uric acid stones are seen . . .
Treatment of hyperhidrosis.
Authors: Lewis P Stolman
Journal: BMJ (1978)

Hyperhidrosis, or excessive sweating, is a disorder that may cause social isolation or occupational disability. It may be generalized or localized, and although frequently idiopathic it may be a manifestation of a number of important systemic diseases. Drugs, surgical procedures, and electrical devices may all be employed by the physician as therapeutic weapons to treat hyperhidrosis.
Déjà vu: Ralstonia mannitolilytica infection associated with a humidifying respiratory therapy device, Israel, June to July 2011
Authors: C Block, Z Ergaz-Shaltiel, L Valinsky, V Temper, C Hidalgo-Grass, N Minster, C Weissman, S Benenson, J Jaffe, A E Moses, B Bar-Oz
Journal: Eurosurveillance (2013)

Following a bloodstream infection in June 2011 with Ralstonia mannitolilytica in a premature infant treated with a humidifying respiratory therapy device, an investigation was initiated at the Hadassah Medical Centres in Jerusalem. The device delivers a warmed and humidified mixture of air and oxygen to patients by nasal cannula. The investigation revealed colonisation with R. mannitolilytica of two of 15 patients and contamination of components of five of six devices deployed in the premature units of the Hadassah hospitals. Ten isolates from the investigation were highly related and indistinguishable from isolates described in an outbreak in 2005 in the United States (US). Measures successful in containing the US outbreak were not included in user instructions provided to our hospitals by the distributor of the device.
Abstract B10: Increased expression of EZH2 and TOP2A predicts for a poorer prognostic outcome in Genitourinary Cancers
Authors: Spencer Rosario, Zafardjan Dalimov, Jason Kirk, Kayla Morrell, Kevin Eng, Leigh Ellis
Journal: Cancer Research (2016)

Abstract The enhancer of Zeste homolog 2 (EZH2), a component of the Polycomb Repressive Complex 2 (PRC2), is an epigenetic silencer that is known to be highly expressed in both metastatic and primary prostate cancer (PCa). More recently, topoisomerase IIα (TOP2A), an enzyme that controls the topologic states of DNA during the cell cycle, has also been identified as being highly expressed in PCa. Both EZH2 and TOP2A have been associated with more aggressive disease and poorer prognostic outcome. During genome-wide analysis, using The Cancer Genome Atlas (TCGA), EZH2 and Top2A were found to be highly positively correlated, most noticeably in PCa and clear cell Renal Cell Carcinoma (ccRCC). As a result, we predicted increased expression of both EZH2 and TOP2A in an individual, would predict for a worse prognostic outcome than either gene being highly expressed alone. Further analysis of the TCGA and Memorial Sloan Kettering Cancer Center (MSKCC) datasets, demonstrated that increased expression of these two genes predicted for a poorer prognostic outcome in genitourinary cancers. In tumor samples with increased expression of EZH2 and TOP2A, as compared to the tumor samples that did not concurrently overexpress both EZH2 and TOP2A, patients displayed worse overall Regression Free Survival (RFS), which were associated with increase hazard ratio, and tumor staging and grades. . As these poor prognostic markers were consistent across multiple cancer subtypes, we are beginning to explore those genes that are differentially expressed in individuals with concurrent high TOP2A and EZH2 as a means of further characterizing this novel phenotype. Since these two genes are targetable by drugs such as etoposide (a TOP2 poison) and DZNep (an EZH2 inhibitor), it makes them attractive candidates for treatment in those individuals who not only have tumors that highly express these two genes, but also those individuals that have exacerbated existing treatment options. Citation Format: Spencer Rosario, Zafardjan Dalimov, Jason Kirk, Kayla Morrell, Kevin Eng, Leigh Ellis. Increased expression of EZH2 and TOP2A predicts for a poorer prognostic outcome in Genitourinary Cancers. [abstract]. In: Proceedings of the AACR Special Conference on Chromatin and Epigenetics in Cancer; Sep 24-27, 2015; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2016;76(2 Suppl):Abstract nr B10.
Fifty months follow-up in patients with locally advanced cervical carcinoma (LACC) treated with low dose bi-weekly (ldbw) gemcitabine and cisplatin plus concurrent accelerated radiotherapy (AR)
Authors: A. M. Alvarez, J. Rodger, G. Cinat, H. Porcella, D. de Dios, S. Gianni, A. Gandur Quiroga, B. Roth, P. Menendez, V. Cuartero, E. Mickiewicz
Journal: Journal of Clinical Oncology (2005)

5074 Background: Evaluate survival in patients with LACC treated with ldbw Gemcitabine plus Cisplatin Methods: Between July 2000 and March 2003, 60 untreated patients with histologically confirmed LACC were included.Median age: 52 years (r: 25–76).Stage of disease:16 patients IIIB; 33 pts.: IIB;8 pts.: IIA and 3 pt.IB Bulky. Treatment Schedule: External beam radiotherapy was administered to the whole pelvic region in 23 fractions, totaling 46 Gy. in 5 weeks, with 2 brachytherapy insertions at the end of the3rd. and 5th week. Total dose delivered in this time to the point A was 85 to 90 Gy. Chemotherapy: Gemcitabine 20 mg/m2/d and Cisplatin 30mg/m2 (maximum total dose: 50 mg) twice weekly. Gemcitabine was started 3 days before radiotherapy with cisplatin, concurrently with radiotherapy. As the first three patients had to delay chemotherapy due to haematologic toxicity cisplatin was administered once weekly thereafter. Results: Toxicity: 60 pts were evaluable for toxicity. One patient had to delay one week the first brachytherapy and suspend one chemotherapy infusion due to abdominal pain and fever. Two other patients could not receive one application of chemotherapy each, due to haematologic toxicity.One death occurred during treatment, due to acute myocardial infarction.No alopecia or mucositis was seen. Thrombocytopenia G2 5 pts.; G3 3 pts. Neutropenia G2 6 pts, G3 1 pt.,G4 1 pt.Anemia G2 11 pts; G3 1.Diarrhea G2 13 pt; G3 1 pts.Nausea and Vomiting: G2 21 pts. Responses: Four patients were not evaluable; due to lost to control.Respones were evaluated one, two and three months(thereafter) after treatment was finished.Response rate: 88,3% with 51 CR (85%), 2 PR (3,33%), 2 SD, 1 patient progressed. After 51 months of follow- up 41 patients (68,3%) are alive,9 dead and 10 lost. The median survival was 47 months(IC:43), the median DFS 38 months(IC:32) Conclusions: The overall response obtained was 53/60 (88,3%) survival rate of 68,3% at 51 months, 37 disease free and 4 with disease.This compares favorably with other international reports. No significant financial relationships to disclose.
"Munchausen" Case
Authors: JUDITH M. DEGLIN
Journal: Annals of Internal Medicine (1975)

Comments and Correction1 May 1975"Munchausen" CaseJUDITH M. DEGLIN, PHARM.D., STUART M. DEGLIN, M.D.JUDITH M. DEGLIN, PHARM.D.Search for more papers by this author, STUART M. DEGLIN, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-82-5-721_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: Fialk and Murray (Ann Intern Med 81: 562, 1974) and Sparandero (Ann Intern Med 82:123, 1975) have reported experiences with a patient having the prolapsing mitral valve syndrome and "Munchausen" syndrome. We have seen a patient, who is probably the same person, at our hospital and have uncovered records of at least 10 admissions to this and other hospitals in the Philadelphia-southern New Jersey area.The patient, a 28-year-old white man, was transferred to Thomas Jefferson University Hospital because of persistent chest pain. He stated that he was hospitalized in October 1973 because of an acute myocardial...Reference1. JERESATY R: Mitral valve prolapse—Click Syndrome. Prog Cardiovasc Dis 40:623-652, 1973 CrossrefGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 May 1975Volume 82, Issue 5Page: 721-722KeywordsIschemia Issue Published: 1 May 1975 PDF DownloadLoading ...
Pancreatitis Secondary to Anti–Programmed Death Receptor 1 Immunotherapy Diagnosed by FDG PET/CT
Authors: Yazan Z. Alabed, Ayaz Aghayev, Christopher Sakellis, Annick D. Van den Abbeele
Journal: Clinical Nuclear Medicine (2015)

A 57-year-old man with metastatic melanoma developed colitis secondary to ipilimumab, a known immune-related adverse event (irAE). The patient then received pembrolizumab immunotherapy, an anti-programmed-death-receptor-1 (PD-1) antibody. Restaging FDG PET/CT study following 3 cycles of therapy demonstrated diffuse increased FDG uptake throughout the body of the pancreas associated with fat stranding in the peripancreatic region, suggestive of pembrolizumab-induced pancreatitis. Although the patient was clinically asymptomatic, diagnosis was biochemically confirmed with elevated amylase and lipase levels. In the era of immunotherapy, it will be critical to recognize irAEs early to allow prompt initiation of appropriate therapy and reduce the risk of long-term sequelae.
Regeneration of the Ureter and the Renal Pelvis in Dogs from Transversely Transected and Anastomosed Strips of the Ureteral Wall. Influence of Long Administration of Azathioprine and Prednisone on the Newly Formed Wall
Authors: A. Borkowski, K. Piechna, J. Wyhowski, Z. Plata
Journal: European Urology (1979)
Case 14-1987
Authors: Richard C. Cabot, Robert E. Scully, Eugene J. Mark, William F. McNeely, Betty U. McNeely
Journal: New England Journal of Medicine (1987)

Presentation of Case A 73-year-old woman was admitted to the hospital because of unstable angina pectoris. She was well until about 10 years earlier, when hypertension was found. Five years before admission there was the onset of chronic stable angina pectoris, which responded to nitroglycerin. During the year or two before entry angina became more frequent and occurred on minimal exertion, including washing dishes; she was occasionally awakened from sleep by chest pain. Sweating and dyspnea frequently accompanied the anginal episodes. During the 15 months before admission she was admitted on five occasions to another hospital because of prolonged anginal . . .
THE PATHOLOGY OF ICTERUS.
Authors: P KLEMPERER
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Freedom
Authors: Mary E Black
Journal: BMJ (2008)

I worry about lots of things these days—my career, my pension, my elderly mother, how my children are doing at school (very well so far . . . but who knows?), road crashes, passive smoking, wrinkles, medical autonomy, insane world politics, global warming.

While I worry a lot, there are some things that I do not need to worry about. I do not need to work for the minimum wage. I do not need to work for less than the minimum wage. I have more than one legal passport and do not need to cross borders stuck in a container. I own my own house in my own name; I do not have to raise my children on a rubbish dump. Even if I hit a financial bad patch I will not need to go on the streets to feed my children (medicine pays more). No one can sell me.

My water is clean and comes from a tap in my house; I have a full fridge. I know enough about health care to get the right treatment. I have international health insurance when abroad and the United Kingdom will offer me enough health services to survive a catastrophic illness and not bankrupt me. I can see, hear, and move around without wheels or aids, so no gathering, concert, or building is out of my reach. I have been educated in the best schools and universities and reached the rank of professor, so if anyone discriminates against me I can at least snub them back and at best take expensively successful legal action.

Another pregnancy is not likely to kill me; I am well fed and close to excellent obstetric services, so I will never face an untended four day obstructed labour, have a dead baby extracted, and then live in the twilight zone of a rectal fistula. My husband or my in-laws will never arrange for my pre-teenage daughter to have her external genitalia cut off, be sold to a trafficker to pay off a gambling debt, or married to an elderly rich landowner.

I have my own bank account and there is money in it that I control; I can get credit. I kept my own name after marriage because I wanted to. I can read, I can speak my mind, I can vote, I can drive a car to work. I can go out at night with my friends. I can wear makeup. I can wear anything I like. That short skirt may look better on someone younger or thinner, but no one can stick me in prison for wearing it.

Yes, I may be worried these days. But I am pretty free, while so many women and girls in this world are not. Just when can they have worries like mine?